EUROPEAN MEDICAL SOLUTIONS S (ALEMS.BR) Stock Fundamental Analysis

EBR:ALEMS • BE0974497290

5.439 EUR
0 (0%)
Last: Mar 2, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

3

ALEMS gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 75 industry peers in the Biotechnology industry. There are concerns on the financial health of ALEMS while its profitability can be described as average. ALEMS has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

5

1. Profitability

1.1 Basic Checks

  • ALEMS had positive earnings in the past year.
  • ALEMS had a positive operating cash flow in the past year.
  • ALEMS had negative earnings in 4 of the past 5 years.
  • The reported operating cash flow has been mixed in the past 5 years: ALEMS reported negative operating cash flow in multiple years.
ALEMS.BR Yearly Net Income VS EBIT VS OCF VS FCFALEMS.BR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5M -10M -15M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 2.24%, ALEMS is in the better half of the industry, outperforming 74.67% of the companies in the same industry.
  • ALEMS has a Return On Equity of 10.45%. This is amongst the best in the industry. ALEMS outperforms 84.00% of its industry peers.
  • ALEMS has a Return On Invested Capital of 4.79%. This is in the better half of the industry: ALEMS outperforms 77.33% of its industry peers.
Industry RankSector Rank
ROA 2.24%
ROE 10.45%
ROIC 4.79%
ROA(3y)-7.51%
ROA(5y)-9.94%
ROE(3y)-29.52%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALEMS.BR Yearly ROA, ROE, ROICALEMS.BR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 -400 -600 -800

1.3 Margins

  • ALEMS's Profit Margin of 2.50% is fine compared to the rest of the industry. ALEMS outperforms 73.33% of its industry peers.
  • ALEMS has a better Operating Margin (4.12%) than 73.33% of its industry peers.
  • In the last couple of years the Operating Margin of ALEMS has grown nicely.
  • ALEMS has a Gross Margin of 21.27%. This is comparable to the rest of the industry: ALEMS outperforms 42.67% of its industry peers.
  • ALEMS's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 4.12%
PM (TTM) 2.5%
GM 21.27%
OM growth 3Y226.24%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.83%
GM growth 5YN/A
ALEMS.BR Yearly Profit, Operating, Gross MarginsALEMS.BR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so ALEMS is destroying value.
  • The number of shares outstanding for ALEMS has been reduced compared to 1 year ago.
  • Compared to 5 years ago, ALEMS has more shares outstanding
  • The debt/assets ratio for ALEMS is higher compared to a year ago.
ALEMS.BR Yearly Shares OutstandingALEMS.BR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
ALEMS.BR Yearly Total Debt VS Total AssetsALEMS.BR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

  • Based on the Altman-Z score of -0.91, we must say that ALEMS is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of -0.91, ALEMS is not doing good in the industry: 61.33% of the companies in the same industry are doing better.
  • ALEMS has a Debt/Equity ratio of 1.22. This is a high value indicating a heavy dependency on external financing.
  • ALEMS's Debt to Equity ratio of 1.22 is in line compared to the rest of the industry. ALEMS outperforms 42.67% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.22
Debt/FCF N/A
Altman-Z -0.91
ROIC/WACC0.79
WACC6.04%
ALEMS.BR Yearly LT Debt VS Equity VS FCFALEMS.BR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M -10M

2.3 Liquidity

  • ALEMS has a Current Ratio of 1.40. This is a normal value and indicates that ALEMS is financially healthy and should not expect problems in meeting its short term obligations.
  • ALEMS's Current ratio of 1.40 is on the low side compared to the rest of the industry. ALEMS is outperformed by 61.33% of its industry peers.
  • ALEMS has a Quick Ratio of 1.40. This is a bad value and indicates that ALEMS is not financially healthy enough and could expect problems in meeting its short term obligations.
  • The Quick ratio of ALEMS (0.87) is worse than 66.67% of its industry peers.
Industry RankSector Rank
Current Ratio 1.4
Quick Ratio 0.87
ALEMS.BR Yearly Current Assets VS Current LiabilitesALEMS.BR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • ALEMS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 4876.36%, which is quite impressive.
  • ALEMS shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 12.39%.
  • The Revenue has been growing slightly by 7.56% on average over the past years.
EPS 1Y (TTM)4876.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%173.33%
Revenue 1Y (TTM)12.39%
Revenue growth 3Y7.56%
Revenue growth 5YN/A
Sales Q2Q%7.52%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ALEMS.BR Yearly Revenue VS EstimatesALEMS.BR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 10M 20M 30M 40M
ALEMS.BR Yearly EPS VS EstimatesALEMS.BR Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 -100 -200 -300

More info and screens

Find the best growth stocksShow best growing peers

2

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 20.14, which indicates a rather expensive current valuation of ALEMS.
  • Based on the Price/Earnings ratio, ALEMS is valued cheaply inside the industry as 82.67% of the companies are valued more expensively.
  • When comparing the Price/Earnings ratio of ALEMS to the average of the S&P500 Index (27.13), we can say ALEMS is valued slightly cheaper.
Industry RankSector Rank
PE 20.14
Fwd PE N/A
ALEMS.BR Price Earnings VS Forward Price EarningsALEMS.BR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

  • ALEMS's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. ALEMS is cheaper than 92.00% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 7.95
ALEMS.BR Per share dataALEMS.BR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8 10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for ALEMS!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

EUROPEAN MEDICAL SOLUTIONS S

EBR:ALEMS (3/2/2026, 7:00:00 PM)

5.439

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)01-19
Earnings (Next)04-13
Inst Owners0.02%
Inst Owner ChangeN/A
Ins Owners1.2%
Ins Owner ChangeN/A
Market Cap23.01M
Revenue(TTM)46.78M
Net Income(TTM)1.17M
Analysts34.29
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 20.14
Fwd PE N/A
P/S 0.49
P/FCF N/A
P/OCF 10.3
P/B 2.06
P/tB 28.72
EV/EBITDA 7.95
EPS(TTM)0.27
EY4.96%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.2
FCFYN/A
OCF(TTM)0.53
OCFY9.71%
SpS11.06
BVpS2.64
TBVpS0.19
PEG (NY)N/A
PEG (5Y)N/A
Graham Number4.01
Profitability
Industry RankSector Rank
ROA 2.24%
ROE 10.45%
ROCE 7.61%
ROIC 4.79%
ROICexc 5.47%
ROICexgc 9.18%
OM 4.12%
PM (TTM) 2.5%
GM 21.27%
FCFM N/A
ROA(3y)-7.51%
ROA(5y)-9.94%
ROE(3y)-29.52%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y196.37%
ROICexgc growth 5YN/A
ROICexc growth 3Y199.14%
ROICexc growth 5YN/A
OM growth 3Y226.24%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.83%
GM growth 5YN/A
F-Score6
Asset Turnover0.89
Health
Industry RankSector Rank
Debt/Equity 1.22
Debt/FCF N/A
Debt/EBITDA 3.27
Cap/Depr 136.82%
Cap/Sales 6.57%
Interest Coverage 2.43
Cash Conversion 53.51%
Profit Quality N/A
Current Ratio 1.4
Quick Ratio 0.87
Altman-Z -0.91
F-Score6
WACC6.04%
ROIC/WACC0.79
Cap/Depr(3y)97.27%
Cap/Depr(5y)N/A
Cap/Sales(3y)6.88%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)4876.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%173.33%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)12.39%
Revenue growth 3Y7.56%
Revenue growth 5YN/A
Sales Q2Q%7.52%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y437.83%
EBIT growth 3Y250.9%
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y70.97%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y233.43%
OCF growth 3Y94.38%
OCF growth 5YN/A

EUROPEAN MEDICAL SOLUTIONS S / ALEMS.BR FAQ

What is the fundamental rating for ALEMS stock?

ChartMill assigns a fundamental rating of 3 / 10 to ALEMS.BR.


What is the valuation status for ALEMS stock?

ChartMill assigns a valuation rating of 2 / 10 to EUROPEAN MEDICAL SOLUTIONS S (ALEMS.BR). This can be considered as Overvalued.


Can you provide the profitability details for EUROPEAN MEDICAL SOLUTIONS S?

EUROPEAN MEDICAL SOLUTIONS S (ALEMS.BR) has a profitability rating of 5 / 10.


Can you provide the financial health for ALEMS stock?

The financial health rating of EUROPEAN MEDICAL SOLUTIONS S (ALEMS.BR) is 1 / 10.